Jolanda Howe - 15 Mar 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
SVP, GLOBAL CONTROLLER
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
15 Mar 2025
Net transactions value
-$2,399,237
Form type
4
Filing time
18 Mar 2025, 21:30:09 UTC
Previous filing
04 Feb 2025
Next filing
19 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +5,315 +126% 9,547 15 Mar 2025 Direct F1
transaction MIRM Common Stock Sale $128,221 -2,900 -30% $44.21 6,647 17 Mar 2025 Direct F2
transaction MIRM Common Stock Options Exercise $155,526 +52,900 +796% $2.94 59,547 17 Mar 2025 Direct
transaction MIRM Common Stock Sale $2,221,626 -50,111 -84% $44.33 9,436 17 Mar 2025 Direct F3, F4
transaction MIRM Common Stock Sale $124,802 -2,789 -30% $44.75 6,647 17 Mar 2025 Direct F3, F5
transaction MIRM Common Stock Sale $80,113 -1,806 -27% $44.36 4,841 17 Mar 2025 Direct F3, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Performance Restricted Stock Units Options Exercise $0 -5,315 -67% $0.000000 2,658 15 Mar 2025 Common Stock 5,315 Direct F1, F7
transaction MIRM Stock Option (right to buy) Options Exercise $0 -52,900 -100% $0.000000 0 17 Mar 2025 Common Stock 52,900 $2.94 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
F3 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 16, 2024.
F4 The weighted average sale price for the transaction reported was $44.33410, and the range of prices were between $43.695 and $44.695. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $44.74811, and the range of prices were between $44.70 and $44.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F6 The weighted average sale price for the transaction reported was $44.35923, and the range of prices were between $43.81 and $44.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F7 The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.
F8 The stock option is fully vested.